Decibel Therapeutics Inc (DBTX)

NASDAQ
7.560
+0.050(+0.67%)
After Hours
7.560
0.000(0.00%)
- Real-time Data
  • Volume:
    13,937
  • Bid/Ask:
    7.000/8.200
  • Day's Range:
    7.440 - 7.600

DBTX Overview

Prev. Close
7.51
Day's Range
7.44-7.6
Revenue
-
Open
7.49
52 wk Range
6.18-24.39
EPS
-0.24
Volume
13,937
Market Cap
188.01M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
40,663
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
24,868,817
Next Earnings Date
Dec 01, 2021
What is your sentiment on Decibel Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Decibel Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellSell
Technical IndicatorsSellBuySellStrong SellSell
SummarySellNeutralSellStrong SellSell

Decibel Therapeutics Inc Company Profile

Decibel Therapeutics Inc Company Profile

Sector
Services
Employees
0

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company’s lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.